These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9512123)

  • 1. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis.
    Giardiello FM; Spannhake EW; DuBois RN; Hylind LM; Robinson CR; Hubbard WC; Hamilton SR; Yang VW
    Dig Dis Sci; 1998 Feb; 43(2):311-6. PubMed ID: 9512123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary chemoprevention of familial adenomatous polyposis with sulindac.
    Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
    N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis.
    Yang VW; Geiman DE; Hubbard WC; Spannhake EW; Hylind LM; Hamilton SR; Giardiello FM
    Prostaglandins Other Lipid Mediat; 2000 Jan; 60(1-3):83-96. PubMed ID: 10680778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac.
    Nugent KP; Spigelman AD; Phillips RK
    Dis Colon Rectum; 1996 Jun; 39(6):659-62. PubMed ID: 8646953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
    Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
    Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis.
    Winde G; Schmid KW; Brandt B; Müller O; Osswald H
    Dis Colon Rectum; 1997 Oct; 40(10):1156-68; discussion 1168-9. PubMed ID: 9336110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
    Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
    Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
    Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
    Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
    Fernández-López F; Conde-Freire R; Cadarso-Suárez C; García-Iglesias J; Puente-Domínguez JL; Potel-Lesquereux J
    Eur J Surg; 2001 May; 167(5):375-81. PubMed ID: 11419555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis.
    Yang VW; Shields JM; Hamilton SR; Spannhake EW; Hubbard WC; Hylind LM; Robinson CR; Giardiello FM
    Cancer Res; 1998 Apr; 58(8):1750-3. PubMed ID: 9563494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention.
    Winde G; Lügering N; Glodny B; Schmid KW; Müller O; Senninger N; Osswald H
    Cancer Lett; 1998 Dec; 134(2):201-7. PubMed ID: 10025882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.
    Chiu CH; McEntee MF; Whelan J
    Cancer Res; 1997 Oct; 57(19):4267-73. PubMed ID: 9331087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
    Alberts DS; Hixson L; Ahnen D; Bogert C; Einspahr J; Paranka N; Brendel K; Gross PH; Pamukcu R; Burt RW
    J Cell Biochem Suppl; 1995; 22():18-23. PubMed ID: 8538196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.
    Matsumoto T; Nakamura S; Esaki M; Yao T; Iida M
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):251-7. PubMed ID: 16460482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
    Hisamuddin IM; Wehbi MA; Chao A; Wyre HW; Hylind LM; Giardiello FM; Yang VW
    Clin Cancer Res; 2004 Dec; 10(24):8357-62. PubMed ID: 15623613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study.
    Schnitzler M; Dwight T; Robinson BG
    Gut; 1996 May; 38(5):707-13. PubMed ID: 8707116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.
    Boon EM; Keller JJ; Wormhoudt TA; Giardiello FM; Offerhaus GJ; van der Neut R; Pals ST
    Br J Cancer; 2004 Jan; 90(1):224-9. PubMed ID: 14710233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.